Clinical Trial

Suprafascial Vancomycin Powder for Prevention of Surgical Site Infections After Instrumented Posterior Spinal Fusion

Study acronym: VANCO

Completed Phase 2

Summary

Surgical site infections (SSI) after spine surgery may occur in up to 12% of cases and can lead to increased morbidity, and healthcare costs In this randomized controlled trial the investigators aim to prospectively investigate the efficacy and safety of suprafascial intrawound vancomycin powder in reducing the rate of SSIs after instrumented spinal fusion surgery. Secondary aims of the study are the incidence of vancomycin-related complications, vancomycin-resistant bacterial infections in the treatment arm as well as the rate of revision surgeries due to SSIs.

Protocol Amendment History 3 changes

critical Trial completed 2026-08-06

notable Primary completion moved earlier: 2026-09-30 -> 2026-06-10 2026-08-06

minor Completion moved earlier: 2027-03-31 -> 2026-07-31 2026-08-06

Trial Details

NCT Number	NCT04017468
Lead Sponsor	Insel Gruppe AG, University Hospital Bern
Conditions	Surgical Site Infection
Enrollment	450 participants
Start Date	2019-10-15
Primary Completion	2026-06-10 (estimated)
Study Completion	2026-07-31 (estimated)
Updated on ClinicalTrials.gov	2026-08-05